The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 8.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (23 analysts) rates it buy, with a mean price target of $5699.
Bank Mandiri
BMRI.JK · IDX · IDR · Market cap $418.13T · 38,777 employees
PT Bank Mandiri (Persero) Tbk provides various banking products and services to individuals and businesses in Indonesia, Singapore, Malaysia, Hong Kong, Timor Leste, Shanghai, England, and the Cayman Islands.
FAIL · Does not pass the screenPrice as of 16 Nov 2026Daily close, not a live quote
Screened 2026-11-16 · the tape above runs as of 10:02 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price3,900.00 IDR at the 16 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 16 Nov 2026
- Our regime readDistribution, as of 15 Nov 2026
- Ethical screenDoes not pass
- Last reviewed16 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: 6,022.21 IDR to 7,780.00 IDR, base estimate 6,800.00 IDR (screen dated 2026-11-16).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Bank Mandiri holds its Distribution at $3,900.00. Consolidating, no directional conviction, held for 19 days.
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 19 days |
| Price at the screen | $3,900.00 |
| Valuation | 6.70 trailing · 6.33 forward price to earnings |
| Values screen | FAIL · score 30.0 |
| Beta | -0.02 |
Five Screens, Shown in Full
Does not pass. Business activity screen
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Bank — FAIL on business activity | Fail |
| Debt load | 7.73% | Below 33% | Interest-bearing debt is just 7.7% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 13.60% | Below 33% | Cash held in interest-bearing accounts and securities is 13.6% of assets, under the one-third limit. | Pass |
| Receivables | 2.25% | Below 49% | Money owed to the company is 2.3% of assets, under the 49% limit. | Pass |
| Revenue purity | 65.33% | Below 5% | 65.3% of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Bank Mandiri does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-11-16. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when BMRI.JK's ethical verdict changes
Today BMRI.JK does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 16 Nov 2026: it trades at roughly a 43% discount to our 6,800.00 IDR fair value, 1.50% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in IDR, drawn from the 2026-11-16 screen. The gold marker is the market price at the same screen. A 42.6% discount to the base estimate.
Third-party analyst targets: 24 covering, consensus Buy. The average target sits +45% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate 6,800.00 IDR, with a range of 6,022.21 IDR to 7,780.00 IDR, dated to the 2026-11-16 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it stands out
A 2%-growth business trading at just 6.3x forward earnings. That is a 43% discount to our 6,800.00 IDR fair value: the market is pricing it cautiously while the fundamentals argue otherwise. 24 analysts rate it Buy with a 5,650.00 IDR average target, about 45% above the screened price.
| Forward P/E | 6.3xexpensive even after accounting for its growth |
| Trailing P/E | 6.7xvery cheap relative to earnings |
| EPS, trailing | 626.75 |
| EPS, forward | 663.48 |
| Revenue growth | +1.5%slow but positive growth |
| Profit margin | 40.2%highly profitable on every dollar of sales |
| Return on equity | 21.0%an exceptional return on shareholder capital |
| Dividend yield | 11.36% |
| Beta | -0.02barely tracks the market's swings |
| 52-week range | 3,650.00 - 5,375.00 |
| Market cap | $418.13T |
| Employees | 38,777 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to Indonesia and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeBMRI.JK trades on IDX (the company is based in Indonesia). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 14.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (23 analysts) rates it buy, with a mean price target of $5699.
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (23 analysts) rates it buy, with a mean price target of $5699.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (23 analysts) rates it buy, with a mean price target of $5699.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 6.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (23 analysts) rates it buy, with a mean price target of $5699.
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (23 analysts) rates it buy, with a mean price target of $5699.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (23 analysts) rates it buy, with a mean price target of $5699. It reported earnings in this window, a natural checkpoint for the thesis.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (23 analysts) rates it buy, with a mean price target of $5699. It reported earnings in this window, a natural checkpoint for the thesis.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (23 analysts) rates it buy, with a mean price target of $5699. It reported earnings in this window, a natural checkpoint for the thesis.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (23 analysts) rates it buy, with a mean price target of $5699. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $4,250.00 | +0.2% | $376.96 | $1,091 | +9.1% |
| 2 months | $4,289.79 | -0.7% | $376.96 | $1,081 | +8.1% |
| 3 months | $4,556.18 | -6.5% | $376.96 | $1,018 | +1.8% |
| 6 months | $4,339.90 | -1.8% | $476.96 | $1,092 | +9.2% |
| 1 year | $4,727.07 | -9.9% | $476.96 | $1,002 | +0.2% |
| 2 years | $5,133.52 | -17.0% | $943.14 | $1,014 | +1.4% |
| 3 years | $3,988.72 | +6.8% | $1,297.10 | $1,393 | +39.3% |
| 5 years | $2,217.57 | +92.1% | $1,742.09 | $2,707 | +170.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever BMRI.JK does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.